These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16612598)

  • 1. Targeted and shielded adenovectors for cancer therapy.
    Hedley SJ; Chen J; Mountz JD; Li J; Curiel DT; Korokhov N; Kovesdi I
    Cancer Immunol Immunother; 2006 Nov; 55(11):1412-9. PubMed ID: 16612598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.
    Jönsson F; Hagedorn C; Kreppel F
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30417881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions.
    Weklak D; Pembaur D; Koukou G; Jönsson F; Hagedorn C; Kreppel F
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
    Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
    Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.
    Kaliberov SA; Kaliberova LN; Buchsbaum DJ; Curiel DT
    Cancer Gene Ther; 2014 Jul; 21(7):264-74. PubMed ID: 24903014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.
    Zhu ZB; Rivera AA; Makhija SK; Lu B; Wang M; Izumi M; Cerfolio RJ; Stoff-Khalili MA; Zhou F; Takayama K; Siegal GP; Curiel DT
    Lung Cancer; 2007 Feb; 55(2):145-56. PubMed ID: 17113184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
    González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
    J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
    Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
    Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
    Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
    Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concepts in Oncolytic Adenovirus Therapy.
    Mantwill K; Klein FG; Wang D; Hindupur SV; Ehrenfeld M; Holm PS; Nawroth R
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.
    Zhu ZB; Makhija SK; Lu B; Wang M; Wang S; Takayama K; Siegal GP; Reynolds PN; Curiel DT
    J Thorac Oncol; 2006 Sep; 1(7):701-11. PubMed ID: 17409940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells.
    Iguchi K; Sakurai F; Tomita K; Katayama K; Yamaguchi T; Kawabata K; Tagawa M; Kawabata M; Shirakawa T; Mizuguchi H
    Cancer Gene Ther; 2012 Feb; 19(2):118-25. PubMed ID: 22076042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector-Host Interactions for Therapy.
    Hagedorn C; Kreppel F
    Hum Gene Ther; 2017 Oct; 28(10):820-832. PubMed ID: 28854810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer.
    Kimball KJ; Rivera AA; Zinn KR; Icyuz M; Saini V; Li J; Zhu ZB; Siegal GP; Douglas JT; Curiel DT; Alvarez RD; Borovjagin AV
    Mol Imaging; 2009; 8(5):264-77. PubMed ID: 19796604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
    Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
    Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral vector-based strategies against infectious disease and cancer.
    Zhang C; Zhou D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2064-2074. PubMed ID: 27105067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation of a triple mosaic adenovirus for cancer gene therapy.
    Tang Y; Wu H; Ugai H; Matthews QL; Curiel DT
    PLoS One; 2009 Dec; 4(12):e8526. PubMed ID: 20046872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.